Manchester, 10 August 2009 DxS Ltd, a personalised medicine company and leader in the provision of companion diagnostics, has today announced the appointment of Dave Clennell as Director of Quality. With demand for the company’s range of mutation test kits continuing to increase, and an imminent FDA pre-market submission for DxS’ TheraScreen®: K-RAS Mutation Kit clinical diagnostic in the US, this is a key leadership appointment for DxS at a time of rapid growth.
Dave has worked in Quality within the healthcare industry for 30 years and has a wealth of experience in FDA-related markets. Prior to joining DxS, Dave worked as International Director of Quality for Lombard Medical Technologies Plc. Other senior roles within Quality include positions at Johnson & Johnson, Genzyme Limited and SmithKline Beecham Pharmaceuticals.
Dr. Stephen Little, CEO of DxS, said: “Dave will be an asset to the Quality department and to the company as a whole. His considerable experience and familiarity with this industry and the associated regulatory hurdles are invaluable as DxS continues to expand and work within new markets.”
Dave Clennell’s appointment is part of DxS’ continued plan for growth which has seen the company more than double in size within the last twelve months with new manufacturing space taken on at their Manchester site. In 2008 DxS signed a global distribution agreement with Roche Molecular Diagnostics for their TheraScreen range of diagnostic kits, and a deal which has seen Amgen and Merck Serono/Bristol Myers Squibb use DxS’ TheraScreen: K-RAS Mutation Kit as a companion diagnostic for the colorectal cancer treatment Vectibix® and Erbitux®. In May DxS announced a deal with Boehringer Ingelheim to provide a companion diagnostic test kit for BIBW 2992 (Tovok™), and in July a deal with Astra Zeneca to develop a companion diagnostic for use with IRESSA™ (gefitinib).
Dave has worked in Quality within the healthcare industry for 30 years and has a wealth of experience in FDA-related markets. Prior to joining DxS, Dave worked as International Director of Quality for Lombard Medical Technologies Plc. Other senior roles within Quality include positions at Johnson & Johnson, Genzyme Limited and SmithKline Beecham Pharmaceuticals.
Dr. Stephen Little, CEO of DxS, said: “Dave will be an asset to the Quality department and to the company as a whole. His considerable experience and familiarity with this industry and the associated regulatory hurdles are invaluable as DxS continues to expand and work within new markets.”
Dave Clennell’s appointment is part of DxS’ continued plan for growth which has seen the company more than double in size within the last twelve months with new manufacturing space taken on at their Manchester site. In 2008 DxS signed a global distribution agreement with Roche Molecular Diagnostics for their TheraScreen range of diagnostic kits, and a deal which has seen Amgen and Merck Serono/Bristol Myers Squibb use DxS’ TheraScreen: K-RAS Mutation Kit as a companion diagnostic for the colorectal cancer treatment Vectibix® and Erbitux®. In May DxS announced a deal with Boehringer Ingelheim to provide a companion diagnostic test kit for BIBW 2992 (Tovok™), and in July a deal with Astra Zeneca to develop a companion diagnostic for use with IRESSA™ (gefitinib).
